The company's financial position is increasingly vulnerable, with total assets declining to $106.0 million and retained earnings reaching a deficit of $354.1 million as of 2026Q1.
| Total Current Assets | 88.74M | 112.67M | 188.63M | 79.82M | 104.67M | 162.29M | 26.11M |
| Cash & Short-Term Investments | 86.78M | 108.01M | 185.43M | 76.97M | 102.53M | 160.92M | 25.44M |
| Cash Only | 20.95M | 26.7M | 40.23M | 53.5M | 102.53M | 160.92M | 25.44M |
| Short-Term Investments | 65.83M | 81.31M | 145.19M | 23.47M | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 146K | 1.76M | 525K | 468K | 0 |
| Days Sales Outstanding | - | - | 212.31 | 19.16 | 38.86 | 85.32 | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - |
| Other Current Assets | 1.96M | 4.66M | 3.06M | 1.09M | 1.62M | 0 | 0 |
| Total Non-Current Assets | 17.21M | 18.27M | 20.95M | 25.29M | 28.37M | 7.64M | 3.13M |
| Property, Plant & Equipment | 16.3M | 17.36M | 20.43M | 24.64M | 27.61M | 4.08M | 2.39M |
| Fixed Asset Turnover | 0.00x | - | 0.01x | 1.36x | 0.18x | 0.49x | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 461K | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 919K | 919K | 525K | 650K | 762K | 3.56M | 732K |
| Total Assets | 105.95M | 130.94M | 209.58M | 105.11M | 133.05M | 169.93M | 29.23M |
| Asset Turnover | 0.00x | - | 0.00x | 0.32x | 0.04x | 0.01x | - |
| Asset Growth % | 7% | -37.52% | 99.38% | -21% | -21.7% | 481.26% | - |
| Total Current Liabilities | 10.88M | 13.09M | 12.25M | 12.23M | 25.63M | 19.3M | 5.76M |
| Accounts Payable | 2.29M | 0 | 1.12M | 614K | 1.1M | 1.44M | 2.15M |
| Days Payables Outstanding | 595.87 | - | - | - | - | - | - |
| Short-Term Debt | 3.04M | 3.06M | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 10.89M | 7.29M | 0 |
| Other Current Liabilities | 5.56M | 10.03M | 0 | 0 | 0 | 0 | 0 |
| Current Ratio | 8.16x | 8.61x | 15.39x | 6.53x | 4.08x | 8.41x | 4.53x |
| Quick Ratio | 8.16x | 8.61x | 15.39x | 6.53x | 4.08x | 8.41x | 4.53x |
| Cash Conversion Cycle | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 7.23M | 7.88M | 10.69M | 254.9M | 248.13M | 239.48M | 45.04M |
| Long-Term Debt | 7.23M | 7.88M | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 18.1M | 0 | 10.61M | 13.32M | 15.96M | 1.31M | 1.66M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 216.41M | 216.41M | 0 |
| Other Non-Current Liabilities | 0 | 0 | 73K | 241.59M | 115K | 81K | 43.38M |
| Total Liabilities | 18.11M | 20.97M | 22.94M | 267.13M | 273.75M | 258.78M | 50.8M |
| Total Debt | 10.26M | 10.94M | 14.35M | 16.91M | 19.45M | 1.74M | 2.12M |
| Net Debt | -10.69M | -15.76M | -25.88M | -36.59M | -83.08M | -159.18M | -23.33M |
| Debt / Equity | 0.12x | 0.10x | 0.08x | - | - | - | - |
| Debt / EBITDA | -0.11x | - | - | - | - | - | - |
| Net Debt / EBITDA | 0.12x | - | - | - | - | - | - |
| Interest Coverage | - | - | - | - | - | - | -88.42x |
| Total Equity | 87.85M | 109.97M | 186.64M | -162.01M | -140.7M | -88.86M | -21.57M |
| Equity Growth % | 53.25% | -41.08% | 215.2% | -15.15% | -58.34% | -312.01% | - |
| Book Value per Share | 3.56 | 4.50 | 7.66 | -6.96 | -8.00 | -5.05 | -1.23 |
| Total Shareholders' Equity | 87.85M | 109.97M | 186.64M | -162.01M | -140.7M | -88.86M | -21.57M |
| Common Stock | 3K | 3K | 3K | 0 | 0 | 0 | 0 |
| Retained Earnings | -354.06M | -330.55M | -246.68M | -181.31M | -152.59M | -93.8M | -21.98M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -18K | 103K | -129K | 308K | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Clinical trial funding dependency
According to reported financial statements, Artiva's total assets have declined from $225.6 million in 2024Q3 to $106.0 million by 2026Q1, reflecting a consistent trajectory of capital consumption as the firm exhausts its available resources to fund ongoing clinical trials for its NK cell therapy pipeline.
The steady contraction in total assets suggests that the company is operating in a capital-intensive phase where internal resource generation is non-existent. Investors should monitor the rate of asset depletion, as the current trend indicates a narrowing window for achieving clinical milestones before additional financing becomes a necessity.
Based on the provided quarterly data, Artiva's cash position has dwindled from $55.9 million in 2024Q3 to $21.0 million in 2026Q1, highlighting a significant reduction in the liquidity buffer available to support the company's high-burn research and development activities over the coming quarters.
While the current ratio remains elevated at 8.16, this metric is somewhat deceptive given the lack of recurring revenue and the high fixed costs associated with clinical trial execution. The rapid decline in absolute cash levels suggests that the company's operational flexibility is becoming increasingly constrained by its reliance on external funding.
As indicated by the company's balance sheet, retained earnings have plummeted to a deficit of $354.1 million as of 2026Q1, a direct consequence of the persistent net losses incurred while advancing its therapeutic candidates through the early stages of the clinical development process.
The negative trajectory of retained earnings underscores the structural challenge of funding long-term biotech innovation without commercial revenue. This persistent erosion of equity suggests that future capital raises may be highly dilutive, as the company lacks the earnings power to support its valuation through internal growth.
Based on reported figures, Artiva's reliance on GC Cell for manufacturing creates a potential distortion in the balance sheet, as the company holds $16.3 million in net PPE while lacking full control over the underlying production infrastructure critical to its off-the-shelf NK cell platform.
This structural dependency implies that the company's asset base may be less flexible than it appears, as the value of its PPE is tied to a specific third-party relationship. Investors should consider whether this manufacturing arrangement limits the company's ability to pivot its cost structure if clinical requirements for cell doses evolve.
Quick answers to the most common questions about buying ARTV stock.
As of 2025, Artiva Biotherapeutics, Inc. (ARTV) had total assets of $130.9M including $112.7M in current assets.
Artiva Biotherapeutics, Inc. (ARTV) carries total debt of $10.9M, offset by $108.0M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Artiva Biotherapeutics, Inc. (ARTV) has total shareholders' equity (book value) of $110.0M ($4.50 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Artiva Biotherapeutics, Inc. (ARTV) reported a current ratio of 8.61x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.